^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ARHGEF7 (Rho Guanine Nucleotide Exchange Factor 7)

    i
    Other names: ARHGEF7, Rho Guanine Nucleotide Exchange Factor 7, P85SPR, COOL1, PIXB, P85, PAK-Interacting Exchange Factor Beta, Nbla10314, KIAA0142, BETA-PIX, P85COOL1, P50BP, PAK3, P50, Rho Guanine Nucleotide Exchange Factor (GEF) 7, SH3 Domain-Containing Proline-Rich Protein, DKFZp686C12170, DKFZp761K1021, COOL-1, Beta-Pix, PAK3BP
    Associations

    News

    Trials
    over2years
    Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma. (PubMed, Heliyon)
    Ultimately, quantitative reverse transcription polymerase chain reaction (RT-PCR) was utilized to validate the expression of the seven pivotal ARGs. In this study, based on seven ARGs, a risk model and nomogram established can be used for risk stratification and prediction of survival outcomes in patients with OSC, providing a reliable reference for individualized therapy of OSC patients.
    Journal
    |
    NOTCH4 (Notch 4) • ARHGEF7 (Rho Guanine Nucleotide Exchange Factor 7) • SKP2 (S-phase kinase-associated protein 2)
    3years
    Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2023 --> Feb 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • RASSF1 (Ras Association Domain Family Member 1) • ARHGEF7 (Rho Guanine Nucleotide Exchange Factor 7) • COL6A2 (Collagen Type VI Alpha 2 Chain) • GPX7 (Glutathione Peroxidase 7) • HOXB4 (Homeobox B4) • RASGRF2 (Ras Protein Specific Guanine Nucleotide Releasing Factor 2) • TM6SF1 (Transmembrane 6 Superfamily Member 1)
    |
    ER positive • HER-2 negative • PGR negative
    |
    carboplatin • albumin-bound paclitaxel • Zolinza (vorinostat)
    almost4years
    SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells. (PubMed, J Biol Chem)
    Finally, we confirmed that the CDCP1-SRC axis was also crucial for HGF and ARHGEF7-RAC1 signaling in MDA-MB-231 cells. Altogether, these results demonstrate that the CDCP1-SRC-ARHGEF7-RAC1 pathway plays an important role in the HGF-induced invasion of a subset of breast cancer cells.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor) • ARHGEF7 (Rho Guanine Nucleotide Exchange Factor 7)
    |
    MET expression
    4years
    Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2022 --> Feb 2023
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • RASSF1 (Ras Association Domain Family Member 1) • ARHGEF7 (Rho Guanine Nucleotide Exchange Factor 7) • COL6A2 (Collagen Type VI Alpha 2 Chain) • GPX7 (Glutathione Peroxidase 7) • HOXB4 (Homeobox B4) • RASGRF2 (Ras Protein Specific Guanine Nucleotide Releasing Factor 2) • TM6SF1 (Transmembrane 6 Superfamily Member 1)
    |
    ER positive • HER-2 negative • PGR negative
    |
    carboplatin • albumin-bound paclitaxel • Zolinza (vorinostat)